NOW APPROVED FOR FIRST-LINE ADVANCED EGFRm NSCLC

FIRST-LINE TAGRISSO® GROUNDBREAKING EFFICACY

18.9 vs 10.2

months median PFS
for the EGFR TKI comparator arm (P<0.0001)
in the FLAURA study1,2

References:
1. AstraZeneca Pharmaceuticals. TAGRISSO® (osimertinib). Summary of Product Characteristics, 2018. 2. Soria J-C, Ohe Y, Vansteenkiste J, et al; FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. N Engl J Med. 2018;378:113-125.